Table 2.
Association between PD-1 Expression in Tumor Cells and Clinical Laboratory Data in DLBCL Cases
| DLBCL-RT N=11 |
DLBCL-de novo N=47 |
|||||
|---|---|---|---|---|---|---|
| PD-1 negative/<30 N=2 cases N/% |
PD-1≥30 N=9 cases N/% |
Test of Significance |
PD-1 negative/ <30 N=2 cases N/% |
PD-1 ≥30 N=5 cases N/% |
Test of Significance |
|
| Age | ||||||
| ≤60 | 1 (50) | 3 (33.3) | ꭓ2FET=0.196 | 23 (54.8) | 3 (60) | ꭓ2FET=0.05 |
| >60 | 1 (50) | 6 (66.7) | P=1.0 | 19 (45.2) | 2 (40) | P=1.0 |
| Gender | ||||||
| Male | 1 (50) | 7 (77.8) | ꭓ2FET=0.637 | 26 (61.9) | 1 (20) | ꭓ2FET=3.21 |
| Female | 1 (50) | 2 (22.2) | P=0.491 | 16 (38.1) | 4 (80) | P=0.148 |
| Lymphocytosis (>5 x 109/L) | ||||||
| Absent | 1 (50) | 4 (44.4) | ꭓ2FET=0.02 | 38 (90.5) | 5 (100) | ꭓ2FET=0.520 |
| Present | 1 (50) | 5 (55.6) | P=1.0 | 4 (9.5) | 0 | P=1.0 |
| Anemia (HB <10 g/L) | ||||||
| Absent | 2 (100) | 6 (66.7) | ꭓ2FET=0.917 | 32 (76.2) | 1 (20) | ꭓ2FET=6.75 |
| Present | 0 | 3 (33.3) | P=1.0 | 10 (23.8) | 4 (80) | P=0.023* |
| Thrombocytopenia (platelets<100 x 109/L) | ||||||
| Absent | 2 (100) | 5 (55.6) | ꭓ2FET=1.39 | 34 (81) | 5 (100) | ꭓ2=1.14 |
| Present | 0 | 4 (44.4) | P=0.491 | 8 (19) | 0 | P=0.571 |
| LDH (>190 U/I) | ||||||
| Not-Elevated | 0 | 0 | …… | 7 (16.7) | 0 | ꭓ2=0.979 |
| Elevated | 2 (100) | 9 (100) | 35 (83.3) | 5 (100) | P=0.322 | |
| First hour ESR | ||||||
| Not-Elevated | 0 | 2 (22.2) | ꭓ2FET=0.543 | 5 (11.9) | 1 (20) | ꭓ2FET=0.393 |
| Elevated | 2 (100) | 7 (77.8) | P=0.461 | 37 (88.1) | 4 (80) | P=0.821 |
| BM involvement | ||||||
| BMA | ||||||
| Negative | 1 (50) | 4 (44.4) | ꭓ2FET=0.02 | 37 (88.1) | 5 (100) | ꭓ2=0.666 |
| Positive | 1 (50) | 5 (55.6) | P=1.0 | 5 (11.9) | 0 | P=1.0 |
| BMB | ||||||
| Negative | 0 | 4 (44.4) | ꭓ2FET=1.39 | 32 (76.2) | 4 (80) | ꭓ2FET=0.036 |
| Positive | 2 (100) | 5 (55.6) | P=0.491 | 10 (23.8) | 1 (20) | P=1.0 |
| Associated malignancy | ||||||
| Absent | 2 (100) | 9 (100) | ……… | 40 (95.2) | 5 (100) | ꭓ2FET=0.249 |
| Present | 0 | 0 | 2 (4.8) | 0 | P=1.0 | |
| B-Symptoms | ||||||
| Absent | 0 | 8 (88.9) | ꭓ2FET=6.52 | 29 (69.0) | 3 (60) | ꭓ2FET=6.52 |
| Present | 2 (100) | 1 (11.1) | P=0.06 | 13 (31.0) | 2 (40) | P=0.06 |
| Viral infection | ||||||
| Absent | 1 (50) | 5 (55.6) | ꭓ2MC=0.356 | 23 (54.8) | 1 (20) | ꭓ2FET=2.16 |
| HCV | 1 (50) | 3 (33.3) | P=0.837 | 19 (45.2) | 4 (80) | P=0.188 |
| HBV | 0 | 1 (11.1) | 0 | 0 | ||
| Lymphadenopathy | ||||||
| Localized | 0 | 0 | ………… | 2 (4.8) | 0 | ꭓ2FET=0.249 |
| Generalized | 2 (100) | 9 (100) | 40 (95.2) | 5 (100) | P=1.0 | |
| Size of excised lymph node (centimeters) | 3.75±0.35 | 3.83±1.78 | t=0.063 p=0.951 |
3.39±1.47 | 2.80±1.15 | t=0.871 p=0.388 |
| DLBCL-RT N=11 |
DLBCL-de novo N=47 |
|||||
| PD-1 negative/<30 N=2 cases N/% |
PD-1≥30 N=9 cases N/% |
Test of Significance |
PD-1 negative/ <30 N=2 cases N/% |
PD-1 ≥30 N=5 cases N/% |
Test of Significance |
|
| Extra nodal site number | ||||||
| Absent | 2 (100) | 5 (55.6) | ꭓ2MC=1.39 | 31 (73.8) | 0 | ꭓ2MC=10.89 |
| One site | 0 | 1 (11.1) | P=0.497 | 7 (16.7) | 3 (60) | P=0.004* |
| >one site | 0 | 3 (33.3) | 4 (9.5) | 2 (40) | ||
| Ann Arbor Stage | ||||||
| I/II | 0 | 1 (11.1) | ꭓ2FET=0.244 | 8 (19.0) | 0 | ꭓ2=1.15 |
| III/IV | 2 (100) | 8 (88.9) | P=1.0 | 34 (81) | 5 (100) | P=0.571 |
| IPI | ||||||
| 0-2 | 1 (50) | 2 (22.2) | ꭓ2FET=0.637 | 26 (61.9) | 2 (40) | ꭓ2FET=0.890 |
| 3-5 | 1 (50) | 7 (77.8) | P=0.491 | 16 (38.1) | 3 (60) | P=0.381 |
N, number; χ2, Chi-Square test; P, Probability value; *statistically significant (P<0.05)